v3.25.2
Revenues (Tables)
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenues by product
Revenue by product is summarized as follows:
 For the Three Months Ended June 30,
20252024
(In millions)United
States		Rest of
World		TotalUnited
States		Rest of
World		Total
Multiple Sclerosis:
TECFIDERA$47.2 $146.4 $193.6 $44.1 $208.1 $252.2 
VUMERITY188.0 24.3 212.3 144.2 21.6 165.8 
Total Fumarate235.2 170.7 405.9 188.3 229.7 418.0 
AVONEX121.7 56.0 177.7 117.2 65.6 182.8 
PLEGRIDY28.3 40.7 69.0 28.2 39.9 68.1 
Total Interferon150.0 96.7 246.7 145.4 105.5 250.9 
TYSABRI272.2 182.4 454.6 248.7 213.5 462.2 
FAMPYRA(1)
— — — — 18.7 18.7 
Subtotal: Multiple Sclerosis657.4 449.8 1,107.2 582.4 567.4 1,149.8 
Rare Disease:
SPINRAZA149.3 243.4 392.7 157.3 271.8 429.1 
SKYCLARYS(2)
78.0 52.3 130.3 75.6 24.4 100.0 
QALSODY(3)
7.5 12.5 20.0 4.6 0.4 5.0 
Subtotal: Rare Disease234.8 308.2 543.0 237.5 296.6 534.1 
Biosimilars:
BENEPALI— 112.1 112.1 — 117.3 117.3 
IMRALDI— 46.7 46.7 — 53.2 53.2 
FLIXABI— 14.3 14.3 — 13.1 13.1 
BYOOVIZ2.5 6.1 8.6 10.3 3.4 13.7 
TOFIDENCE— — — 0.8 — 0.8 
Subtotal: Biosimilars2.5 179.2 181.7 11.1 187.0 198.1 
Other:
ZURZUVAE46.4 — 46.4 14.9 — 14.9 
Other(4)
— 0.4 0.4 0.8 1.9 2.7 
Subtotal: Other46.4 0.4 46.8 15.7 1.9 17.6 
Total product revenue, net$941.1 $937.6 $1,878.7 $846.7 $1,052.9 $1,899.6 
(1) Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.
(2) SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.
(3) QALSODY became commercially available in the E.U. during the second quarter of 2024.
(4) Other includes FUMADERM and ADUHELM.
 For the Six Months Ended June 30,
20252024
(In millions)United
States		Rest of
World		TotalUnited
States		Rest of
World		Total
Multiple Sclerosis:
TECFIDERA$87.0 $312.7 $399.7 $87.8 $418.7 $506.5 
VUMERITY305.1 46.0 351.1 250.1 43.2 293.3 
Total Fumarate392.1 358.7 750.8 337.9 461.9 799.8 
AVONEX230.3 114.2 344.5 228.4 132.9 361.3 
PLEGRIDY52.4 76.1 128.5 56.8 76.4 133.2 
Total Interferon282.7 190.3 473.0 285.2 209.3 494.5 
TYSABRI473.0 363.1 836.1 462.5 431.0 893.5 
FAMPYRA(1)
— 0.3 0.3 — 37.9 37.9 
Subtotal: Multiple Sclerosis1,147.8 912.4 2,060.2 1,085.6 1,140.1 2,225.7 
Rare Disease:
SPINRAZA303.7 512.9 816.6 305.8 464.6 770.4 
SKYCLARYS(2)
147.1 107.1 254.2 148.6 29.4 178.0 
QALSODY(3)
15.0 20.5 35.5 9.0 0.6 9.6 
Subtotal: Rare Disease465.8 640.5 1,106.3 463.4 494.6 958.0 
Biosimilars:
BENEPALI— 223.4 223.4 — 236.0 236.0 
IMRALDI— 94.1 94.1 — 108.0 108.0 
FLIXABI— 27.4 27.4 — 30.9 30.9 
BYOOVIZ6.7 10.8 17.5 14.0 5.3 19.3 
TOFIDENCE0.1 — 0.1 0.8 — 0.8 
Subtotal: Biosimilars6.8 355.7 362.5 14.8 380.2 395.0 
Other:
ZURZUVAE74.1 — 74.1 27.3 — 27.3 
Other(4)
0.4 1.7 2.1 1.7 3.8 5.5 
Subtotal: Other74.5 1.7 76.2 29.0 3.8 32.8 
Total product revenue, net$1,694.9 $1,910.3 $3,605.2 $1,592.8 $2,018.7 $3,611.5 
(1) Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.
(2) SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.
(3) QALSODY became commercially available in the E.U. during the second quarter of 2024.
(4) Other includes FUMADERM and ADUHELM.
Analysis of change In reserves
An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Balance, December 31, 2024$162.7 $880.8 $48.1 $1,091.6 
Current provisions relating to sales in current year394.1 1,402.1 14.9 1,811.1 
Adjustments relating to prior years1.4 (63.7)3.3 (59.0)
Payments/credits relating to sales in current year(290.4)(744.1)(0.2)(1,034.7)
Payments/credits relating to sales in prior years(91.8)(440.4)(5.8)(538.0)
Balance, June 30, 2025$176.0 $1,034.7 $60.3 $1,271.0 
Total reserves included in consolidated balance sheets
The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions)As of June 30, 2025As of December 31, 2024
Reduction of accounts receivable$273.6 $154.1 
Component of accrued expense and other997.4 937.5 
Total revenue-related reserves$1,271.0 $1,091.6 
Revenues from anti-CD20 therapeutic programs
Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 For the Three Months Ended June 30,For the Six Months Ended June 30,
(In millions)2025202420252024
Royalty revenue on sales of OCREVUS$353.8 $336.3 $642.6 $639.0 
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO107.7 103.4 191.4 190.5 
Other revenue from anti-CD20 therapeutic programs5.8 4.8 11.5 9.0 
Total revenue from anti-CD20 therapeutic programs$467.3 $444.5 $845.5 $838.5 
Other revenues
Contract manufacturing, royalty and other revenue is summarized as follows:
 For the Three Months Ended June 30,For the Six Months Ended June 30,
(In millions)2025202420252024
Contract manufacturing revenue$225.0 $100.0 $507.3 $252.2 
Royalty and other revenue
19.6 9.0 30.6 38.6 
Total contract manufacturing, royalty and other revenue$244.6 $109.0 $537.9 $290.8